摘要
目的研讨痰热清注射液在心力衰竭伴肺部感染患者中的临床治疗效果及安全性,为提高临床疗效提供依据。方法选取2013年10月-2015年10月医院诊治80例心力衰竭伴肺部感染患者资料进行分析,根据随机数字方法将其分为对照组与观察组,每组各40例;对照组患者采用常规方法治疗,试验组在对照组基础上联合痰热清注射液治疗,比较两组患者临床疗效,数据采用SPSS 18.0软件进行统计分析。结果试验组治疗总有效率为95.0%,显著高于对照组的85.0%(P<0.05);试验组治疗药物不良反应发生率为7.5%,显著低于对照组的17.5%,差异有统计学意义(P<0.05)。结论心力衰竭伴肺部感染患者在常规治疗基础上联合痰热清注射液治疗效果理想,能够提高临床疗效,安全性高,值得推广应用。
OBJECTIVE To study the clinical efficacy and safety of Tanreqing in treatment of heart failure patients with pulmonary infection,so as to provide the basis for improving clinical efficacy.METHODS A total of 80 cases of patients with heart failure and pulmonary infection treated in hospital from Oct.2013 to Oct.2015 were selected,and randomly divided into two groups according to the random number method,with 40 cases in each group.Patients in control group were treated with conventional therapy,and in experimental group were treated with Tanreqing based on control group.The clinical efficacy of the two group were compared,and the data were analyzed by SPSS 18.0.RESULTS The total effective rate of experimental group was 95.0%,significantly higher than 85.0% of control group（P〈0.05）,and the therapy adverse reactions rate of experimental group was 7.5%,significantly lower than 17.5% of control group（P〈0.05）.CONCLUSION Conventional treatment combined with Tanreqing has better efficacy in treatment of heart failure patients with pulmonary infection,which can improve the clinical efficacy,and is safety,so it should be widely applied.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2016年第15期3400-3402,共3页
Chinese Journal of Nosocomiology
基金
青海省自然科学基金资助项目(201204151)
